• Contact Us
TriSalus Life Sciences
  • Our Story
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Boards
  • Our Passion
  • Our Approach
    • Multi-Pronged Approach
    • Immunomodulation
      • Toll-Like Receptor 9 Agonist
    • Drug Delivery
    • Our Products
  • Our Therapeutic Pipeline
    • Pipeline Overview
    • Product Candidates
      • SD-101
    • Clinical Trials for Healthcare Professionals
    • Scientific Publications & Presentations
  • Patients & Caregivers
    • Patients
    • Our Team Approach
    • Clinical Trials for Patients
    • Patient Resources
  • News & Events
    • News
    • Events
Select Page

End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis

by Peter R | Jan 1, 2019 | Drug Delivery, Publications and Presentations

Abstract No. 133 Surefire Infusion System (SIS) hepatocellular carcinoma registry study interim results: a multicenter study of the safety, feasibility, and outcomes of the SIS expandable-tip microcatheter in DEB-TACE

by Peter R | Apr 1, 2018 | Drug Delivery, Publications and Presentations

Short-term imaging response after drug-eluting embolic trans-arterial chemoembolization delivered with the Surefire Infusion System® for the treatment of hepatocellular carcinoma

by Peter R | Sep 1, 2017 | Drug Delivery, Publications and Presentations

Surefire Medical’s Infusion Technology Studied for Treatment of Primary Liver Cancer

by Peter R | Mar 1, 2017 | Drug Delivery, Publications and Presentations

End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis

by Peter R | Aug 1, 2015 | Drug Delivery, Publications and Presentations

The Impact of an Antireflux Catheter on Target Volume Particulate Distribution in Liver-Directed Embolotherapy: A Pilot Study

by Peter R | May 1, 2015 | Drug Delivery, Publications and Presentations

Recent Posts

  • TriSalus Life Sciences Provides Update on Development of Immunotherapy Platform Approach for Liver and Pancreatic Tumors
  • TriSalus Life Sciences to Present at the Society of Interventional Radiology’s 2022 Annual Scientific Meeting
  • TriSalus Life Sciences to Present at the Society of Interventional Radiology’s 2022 Annual Scientific Meeting
  • TriSalus Life Sciences Enrolls First Patient in PERIO-02 Clinical Trial, Studying the Delivery of SD-101 via Pressure-Enabled Drug Delivery in Adults with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
  • PERIO-01: Enabling tumor microenvironment reprogramming by a TLR9 agonist using Pressure-Enabled Drug Delivery™ (PEDD™) to address intrahepatic immunosuppression and drug delivery barriers

Recent Comments

    Our Story Our Passion Our Approach Our Therapeutic Pipeline Patients & Caregivers News Events

    TriSalus Life Sciences
    6272 W. 91st Avenue
    Westminster, CO 80031

       

    © 2021 TriSalus™    All Rights Reserved   Privacy Policy   Compliance    Terms of Use

    You are now leaving the TriSalus Life Sciences corporate website.

    We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from TriSalus' standards.

    Third Party Sites
    TriSalus assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site's endorsement of TriSalus or this website.

    Thank you for visiting our site.